Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored

“…Prostate cancer (PCa) is the second most common neoplasm in men and the fifth leading cause of death worldwide [1]. Despite recent advancements in the diagnosis and treatment of this disease, the incidence of PCa is rising and the clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) are still poor [2,3]. Excluding advanced age and African American ancestries, the only currently identified risk factor for the development of PCa is a positive family history.…”

Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic

“…In some clinical settings, both oral and intravenous agents are indicated. For example, in prostate cancer patients with metastatic castration-sensitive disease, both novel hormonal agents including abiraterone, apalutamide, and enzalutamide and chemotherapy-based docetaxel have been shown to provide a survival advantage ( 20 ). While in the universal Italian health care system, an oral hormonal agent is more likely to be preferred over docetaxel in view of a more favorable safety profile as well as reduced risk of hospitalization and need for in-person visits, some patients in the US may not afford such an expensive and prolonged treatment and prefer a short course of docetaxel.…”

Urologic Malignancies: Advances in the Analysis and Interpretation of Clinical Findings

“…A recently conducted network meta-analysis showed that while men with castration-sensitive prostate cancer treated with either docetaxel or an ARAT agent as first-line therapy reported an overall hazard ratio (HR) for death of 0.69 (95% CI: 0.61-0.78), those treated with an ARAT agent versus docetaxel showed a HR for death favoring the ARAT group of 0.78 (95% CI: 0.67-0.91) [4]. Conversely, sequential or concomitant use of docetaxel plus an ARAT agent in the castration-sensitive setting is not expected to provide any additional benefit compared with the use of an ARAT agent alone [5]. Significant progresses have been made with the results obtained with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which was capable of prolonging survival in selected men with mutations in BRCA1, BRCA2 or ATM genes [6].…”

“…In prostate cancer, our work group conducted two observational studies in patients treated with the taxane agent cabazitaxel after failure of docetaxel and showed that a higher Gleason score was associated with improved efficacy of cabazitaxel [11] and that baseline neutrophil count of less than 4570/mm was associated with increased risk of severe neutropenia [12]. Also, meta-analysis of published trials on the use of ARAT agents in the metastatic castration-sensitive setting showed that a high tumor volume according to the CHAARTED criteria and presence of visceral metastasis were associated with decreased progression-free survival outcomes [5].…”